Mutation of CEP72 Gene May Predispose Patients to Hepatotoxicity.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
26
7
2019
medline:
31
12
2020
entrez:
26
7
2019
Statut:
ppublish
Résumé
Drug toxicities during treatment of acute lymphoblastic leukemia play a pivotal role in influencing the outcome as certain toxicities may impair treatment compliance. Polymorphisms in CEP72 have been linked to increased incidence of vincristine-induced toxicities, namely peripheral neuropathy. We hypothesize that polymorphisms in the same gene may increase a patient's risk of developing hepatotoxicity when receiving potentially hepatotoxic agents during chemotherapy. This report describes hepatotoxicity that first developed during consolidation in a patient homozygous for the CEP72 risk alleles. Bilirubin levels normalized following dose reduction of 6-mercaptopurine. The patient continues to tolerate maintenance therapy at a reduced dose of 6-mercaptopurine.
Identifiants
pubmed: 31343483
doi: 10.1097/MPH.0000000000001568
pii: 00043426-202010000-00029
doi:
Substances chimiques
CEP72 protein, human
0
Microtubule-Associated Proteins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e634-e636Références
Katz AJ, Chia VM, Schoonen WM, et al. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26:1627–1642.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178.
Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–549.
Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407–417.
Crawford JM, Gollan JL. Hepatocyte cotransport of taurocholate and bilirubin glucuronides: role of microtubules. Am J Physiol. 1988;255 (pt 1):G121–G131.
Crawford JM, Berken CA, Gollan JL. Role of the hepatocyte microtubular system in the excretion of bile salts and biliary lipid: implications for intracellular vesicular transport. J Lipid Res. 1988;29:144–156.
Padda MS, Sanchez M, Akhtar AJ, et al. Drug-induced cholestasis. Hepatology. 2011;53:1377–1387.
el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer. 1984;54:2006–2008.
Dean LPratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A. Mercaptopurine therapy and TPMT genotype. Medical Genetics Summaries. Bethesda, MD: National Center for Biotechnology Information; 2012. Available at: https://www.ncbi.nlm.nih.gov/books/NBK100660/.
Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2012;68:1233–1242.
Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815–823.
Principles and Practice of Pediatric Oncology. Philadelphia, PA: Wolters Kluwer; 2016.
Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317–1327.
Stollman YR, Theilmann L, Stockert RJ, et al. Reduced transport of bilirubin and asialoorosomucoid in regenerating rat liver is a microtubule-independent event. Hepatology. 1985;5:798–804.
Oshimori N, Li X, Ohsugi M, et al. Cep72 regulates the localization of key centrosomal proteins and proper bipolar spindle formation. EMBO J. 2009;28:2066–2076.